See more : VIB Vermögen AG (VIH1.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Lannett Company, Inc. (LCI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lannett Company, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Geo-Jade Petroleum Corporation (600759.SS) Income Statement Analysis – Financial Results
- Eddy Smart Home Solutions Ltd. (EDY.V) Income Statement Analysis – Financial Results
- Kobe Steel, Ltd. (KBSTF) Income Statement Analysis – Financial Results
- Directel Holdings Limited (8337.HK) Income Statement Analysis – Financial Results
- Vast Renewables Limited (VSTE) Income Statement Analysis – Financial Results
Lannett Company, Inc. (LCI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.lannett.com
About Lannett Company, Inc.
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 340.58M | 478.78M | 545.74M | 655.41M | 684.56M | 637.34M | 566.09M | 406.84M | 273.77M | 151.05M | 122.99M | 106.84M | 125.18M | 119.00M | 72.40M | 82.58M | 64.06M | 44.90M | 63.78M | 42.49M | 25.13M | 12.09M | 11.55M | 10.60M | 9.46M | 3.80M | 3.82M |
| Cost of Revenue | 307.41M | 403.19M | 380.52M | 411.80M | 395.86M | 332.13M | 256.00M | 100.48M | 119.36M | 93.63M | 84.04M | 83.52M | 83.84M | 73.76M | 54.08M | 57.39M | 33.90M | 31.42M | 26.86M | 16.26M | 8.45M | 6.53M | 7.89M | 6.60M | 6.12M | 2.64M | 1.87M |
| Gross Profit | 33.17M | 75.59M | 165.22M | 243.61M | 288.71M | 305.21M | 310.09M | 306.36M | 154.41M | 57.42M | 38.95M | 23.32M | 41.34M | 45.24M | 18.32M | 25.18M | 30.16M | 13.48M | 36.92M | 26.23M | 16.67M | 5.56M | 3.66M | 4.00M | 3.34M | 1.16M | 1.95M |
| Gross Profit Ratio | 9.74% | 15.79% | 30.27% | 37.17% | 42.17% | 47.89% | 54.78% | 75.30% | 56.40% | 38.01% | 31.67% | 21.83% | 33.02% | 38.02% | 25.31% | 30.50% | 47.08% | 30.03% | 57.89% | 61.73% | 66.36% | 45.95% | 31.70% | 37.74% | 35.33% | 30.64% | 51.10% |
| Research & Development | 22.36M | 24.17M | 29.98M | 38.81M | 29.20M | 42.07M | 45.05M | 30.34M | 27.71M | 16.25M | 11.84M | 8.59M | 11.25M | 8.43M | 5.17M | 7.46M | 8.10M | 6.27M | 5.90M | 2.58M | 1.75M | 1.40M | 730.65K | 900.00K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 82.20M | 73.48M | 0.00 | 49.53M | 38.61M | 22.41M | 20.19M | 15.91M | 17.38M | 26.06M | 16.79M | 14.13M | 11.80M | 9.19M | 8.86M | 4.34M | 3.30M | 2.01M | 1.36M | 1.20M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 81.02M | 68.08M | 79.47M | 87.65M | 82.20M | 73.48M | 68.33M | 49.53M | 38.61M | 22.41M | 20.19M | 15.91M | 17.38M | 26.06M | 16.79M | 14.13M | 11.80M | 9.19M | 8.86M | 4.34M | 3.30M | 2.01M | 1.36M | 1.20M | 0.00 | 0.00 | 0.00 |
| Other Expenses | 178.00K | -1.66M | -840.00K | -2.02M | 47.62M | 99.22M | 68.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -230.57K | 9.55M | 1.80M | 51.66M | 1.33M | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 1.66M | 1.24M | 1.26M |
| Operating Expenses | 103.39M | 92.25M | 109.45M | 126.46M | 111.39M | 115.55M | 113.38M | 79.87M | 66.32M | 38.66M | 32.04M | 24.50M | 28.63M | 34.49M | 21.73M | 31.15M | 21.71M | 67.12M | 16.09M | 6.91M | 5.05M | 3.42M | 2.09M | 2.20M | 1.66M | 1.24M | 1.26M |
| Cost & Expenses | 410.80M | 495.44M | 489.97M | 538.25M | 507.25M | 447.68M | 369.38M | 180.35M | 185.68M | 132.30M | 116.08M | 108.01M | 112.46M | 108.24M | 75.81M | 88.54M | 55.61M | 98.54M | 42.95M | 23.17M | 13.50M | 9.95M | 9.98M | 8.80M | 7.78M | 3.87M | 3.13M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 425.00K | 295.00K | 116.00K | 142.00K | 90.99K | 62.33K | 209.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 57.98M | 53.83M | 66.85M | 84.62M | 85.63M | 89.42M | 65.94M | 207.00K | 130.00K | 251.00K | 273.00K | 214.52K | 275.87K | 321.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 178.00K | -1.66M | 56.31M | 55.59M | 55.12M | 55.34M | 33.43M | 5.58M | 5.98M | 6.20M | 5.74M | 4.98M | 4.89M | 5.10M | 5.23M | 4.47M | 3.97M | 6.97M | 2.51M | 982.19K | 789.30K | 767.05K | 678.63K | 600.00K | 369.37K | 206.69K | 204.27K |
| EBITDA | -176.27M | -18.32M | 54.94M | 115.14M | 191.84M | 145.28M | 161.47M | 233.14M | 96.07M | 27.07M | 12.56M | 4.45M | 17.80M | 16.05M | -464.71K | -1.46M | 12.50M | -46.85M | 23.32M | 19.98M | 11.97M | 3.60M | 1.56M | 1.50M | 1.25M | -582.65K | 341.33K |
| EBITDA Ratio | -20.57% | -3.83% | 10.07% | 17.57% | 28.02% | 22.79% | 28.52% | 57.31% | 35.09% | 17.92% | 10.21% | 4.17% | 14.22% | 13.48% | -0.64% | -1.76% | 19.51% | -104.35% | 36.56% | 47.04% | 47.64% | 29.81% | 13.53% | 14.15% | 13.15% | -15.33% | 8.94% |
| Operating Income | -70.22M | -16.66M | -1.37M | 59.54M | 129.70M | 86.45M | 130.76M | 226.49M | 88.09M | 18.76M | 6.91M | -994.95K | 13.03M | 10.78M | -5.43M | -5.96M | 8.45M | -53.64M | 20.83M | 19.32M | 11.63M | 2.14M | 1.58M | 1.80M | 1.68M | -72.12K | 691.34K |
| Operating Income Ratio | -20.62% | -3.48% | -0.25% | 9.08% | 18.95% | 13.56% | 23.10% | 55.67% | 32.18% | 12.42% | 5.62% | -0.93% | 10.41% | 9.06% | -7.50% | -7.22% | 13.20% | -119.46% | 32.66% | 45.46% | 46.27% | 17.69% | 13.63% | 16.98% | 17.75% | -1.90% | 18.10% |
| Total Other Income/Expenses | -163.71M | -286.19M | -47.25M | -405.79M | -78.60M | -85.90M | -68.58M | 935.00K | 1.93M | 1.93M | -292.00K | 293.58K | -208.95K | -112.56K | -213.23K | 43.33K | 76.18K | -185.84K | -21.20K | -314.60K | -446.22K | 698.11K | -690.26K | -900.00K | -804.32K | -78.76K | -554.27K |
| Income Before Tax | -233.92M | -302.85M | -48.63M | -346.25M | 51.09M | 550.00K | 62.18M | 227.42M | 90.02M | 20.69M | 6.62M | -701.37K | 12.82M | 10.67M | -5.64M | -5.92M | 8.53M | -53.83M | 20.81M | 19.00M | 11.18M | 2.84M | 884.77K | 900.00K | 875.72K | -150.88K | 137.07K |
| Income Before Tax Ratio | -68.68% | -63.25% | -8.91% | -52.83% | 7.46% | 0.09% | 10.98% | 55.90% | 32.88% | 13.69% | 5.38% | -0.66% | 10.24% | 8.96% | -7.79% | -7.17% | 13.32% | -119.87% | 32.63% | 44.72% | 44.50% | 23.47% | 7.66% | 8.49% | 9.25% | -3.97% | 3.59% |
| Income Tax Expense | -2.30M | 60.63M | -15.26M | -74.14M | 22.40M | 1.10M | 17.32M | 77.43M | 32.86M | 7.30M | 2.60M | -461.57K | 4.81M | 4.09M | -3.38M | 1.01M | 3.56M | -21.05M | 7.59M | 7.33M | 3.98M | 1.01M | -465.33K | -400.00K | -150.00K | -78.76K | -554.27K |
| Net Income | -231.62M | -363.48M | -33.37M | -272.11M | 28.69M | -581.00K | 44.78M | 149.92M | 57.10M | 13.32M | 3.95M | -276.90K | 7.82M | 6.53M | -2.32M | -6.93M | 4.97M | -32.78M | 13.22M | 11.67M | 7.20M | 1.83M | 1.35M | 1.30M | 1.03M | -789.34K | 137.07K |
| Net Income Ratio | -68.01% | -75.92% | -6.11% | -41.52% | 4.19% | -0.09% | 7.91% | 36.85% | 20.86% | 8.82% | 3.21% | -0.26% | 6.25% | 5.49% | -3.20% | -8.39% | 7.76% | -73.00% | 20.72% | 27.46% | 28.64% | 15.13% | 11.69% | 12.26% | 10.84% | -20.77% | 3.59% |
| EPS | -22.96 | -36.91 | -3.46 | -28.81 | 0.19 | 0.00 | 0.31 | 1.05 | 0.42 | 0.12 | 0.03 | 0.00 | 0.08 | 0.07 | -0.02 | -0.07 | 0.05 | -0.34 | 0.16 | 0.15 | 0.09 | 0.02 | 0.02 | 0.04 | 0.03 | -0.03 | 0.00 |
| EPS Diluted | -22.96 | -36.91 | -3.46 | -28.81 | 0.19 | 0.00 | 0.30 | 1.01 | 0.41 | 0.12 | 0.03 | 0.00 | 0.08 | 0.07 | -0.02 | -0.07 | 0.05 | -0.34 | 0.16 | 0.15 | 0.09 | 0.02 | 0.02 | 0.04 | 0.03 | -0.03 | 0.00 |
| Weighted Avg Shares Out | 10.09M | 9.85M | 9.65M | 9.44M | 152.65M | 147.25M | 145.77M | 143.31M | 134.65M | 113.87M | 113.05M | 107.03M | 98.98M | 97.79M | 96.91M | 95.57M | 94.65M | 96.41M | 83.91M | 80.46M | 79.96M | 91.50M | 79.24M | 31.20M | 30.77M | 31.24M | 31.24M |
| Weighted Avg Shares Out (Dil) | 10.09M | 9.85M | 9.65M | 9.44M | 152.65M | 147.25M | 149.56M | 148.51M | 140.77M | 115.77M | 113.63M | 107.03M | 100.80M | 98.35M | 96.91M | 95.57M | 94.65M | 96.41M | 83.91M | 80.46M | 79.96M | 91.50M | 79.24M | 31.20M | 30.77M | 31.24M | 79.24M |
Global IT Support Services Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024
Custom Applications Development Service Market | Rising Adoption of Cloud-based Services to Boost the Market Growth | Technavio
Sensex, Nifty end with modest gains in choppy session; HCL Tech, Infy top charts
Google contractor accused of retaliation against unionized employees
Mainframe Market: Leading Manufacturers Expected to Motivate Growth during 2020-2025
Cyber Security Market: Leading Manufacturers Expected to Motivate Growth during 2020-2025
Global BPO Market Size 2020 Company Overview, Growth and Forecast By 2025 Latest Research Report by Industry Research Co
India stocks higher at close of trade; Nifty 50 up 0.82%
Source: https://incomestatements.info
Category: Stock Reports